First-in-human phase I study of givastomig, a novel Claudin 18.2/4-1BB bispecific antibody in advanced solid tumors

被引：1
|
作者：
Ku, G. [1 ]
Shen, L. [2 ]
Klempner, S. J. [3 ]
Pan, H. [4 ]
Kratz, J. [5 ]
Liang, X. [6 ]
Deng, Y. [7 ]
Kim, S. [8 ]
Wang, Z. [9 ]
Feller, L. [10 ]
Powderly, J. [11 ]
Dayyani, F. [12 ]
Schneider, R. E. [13 ]
Girda, E. [14 ]
Berlin, J. D. [15 ]
Spencer, K. [16 ]
Nguyen, M. T. [17 ]
Wang, V. [17 ]
Xu, C. [17 ]
Zhu, A. [18 ]
机构：
[1] MSKCC Mem Sloan Kettering Canc Ctr, Dept Med, Gastrointestinal Oncol Serv, New York, NY USA
[2] Peking Univ Canc Hosp & Inst, GI Oncol Dept, Beijing, Peoples R China
[3] MGH Massachusetts Gen Hosp, Med Oncol Dept, Boston, MA USA
[4] Zhejiang Univ, Sir Run Run Run Shaw Hosp, Med, Sch Med, Hangzhou, Zhejiang, Peoples R China
[5] Univ Wisconsin, Med, Sch Med & Publ Hlth Med Phys, Madison, WI USA
[6] HuBei Canc Hosp, Med Dept, Wuhan, Peoples R China
[7] Sun Yat Sen Univ, Affiliated Hosp 6, Med, Guangzhou, Guangdong, Peoples R China
[8] Univ Colorado, Med Oncol Dept, UCHlth Canc Care, Ctr Canc, Anschutz Med Campus, Aurora, CO USA
[9] China Med Univ, Med, Affiliated Hosp 1, Shenyang, Peoples R China
[10] Horizon BioAdvance, Med Oncol Dept, Lafayette, LA USA
[11] Carolina BioOncol Inst, Oncol, Huntersville, NC USA
[12] UCI Univ Calif Irvine, Med Dept, Hlth Manchester Pavil, Orange, CA USA
[13] Mary Crowley Canc Res Ctr, Med Oncol Dept, Dallas, TX USA
[14] Rutgers Canc Inst New Jersey, Med Oncol Dept, New Brunswick, NJ USA
[15] Vanderbilt Univ, Med Dept, Med Ctr, Preston Canc Res Bldg, Nashville, TN USA
[16] NYU, Med Dept, Langone Laura & Isaac Perlmutter Canc Ctr, New York, NY USA
[17] I Mab Biopharma, Res & Dev, San Diego, CA USA
[18] I Mab Biopharma Co Ltd Headquarter, Res & Dev, Shanghai, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2178
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1039P
引用
收藏
页码：S631 / S631
页数：1
相关论文
共 50 条
  • [21] Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors
    Muik, Alexander
    Garralda, Elena
    Altintas, Isil
    Gieseke, Friederike
    Geva, Ravit
    Ben-Ami, Eytan
    Maurice-Dror, Corinne
    Calvo, Emiliano
    LoRusso, Patricia M.
    Alonso, Guzman
    Rodriguez-Ruiz, Maria E.
    Schoedel, Kristina B.
    Blum, Jordan M.
    Sanger, Bianca
    Salcedo, Theodora W.
    Burm, Saskia M.
    Stanganello, Eliana
    Verzijl, Dennis
    Vascotto, Fulvia
    Sette, Angelica
    Quinkhardt, Juliane
    Plantinga, Theo S.
    Toker, Aras
    van den Brink, Edward N.
    Fereshteh, Mark
    Diken, Mustafa
    Satijn, David
    Kreiter, Sebastian
    Breij, Esther C. W.
    Bajaj, Gaurav
    Lagkadinou, Eleni
    Sasser, Kate
    Tureci, Ozlem
    Forssmann, Ulf
    Ahmadi, Tahamtan
    Sahin, Ugur
    Jure-Kunkel, Maria
    Melero, Ignacio
    CANCER DISCOVERY, 2022, 12 (05) : 1248 - 1265
  • [22] A First-in-Human Phase I Study of MORAb-004, a Monoclonal Antibody to Endosialin in Patients with Advanced Solid Tumors
    Diaz, Luis A., Jr.
    Coughlin, Christina M.
    Weil, Susan C.
    Fishel, Jean
    Gounder, Mrinal M.
    Lawrence, Susan
    Azad, Nilofer
    O'Shannessy, Daniel J.
    Grasso, Luigi
    Wustner, Jason
    Ebel, Wolfgang
    Carvajal, Richard D.
    CLINICAL CANCER RESEARCH, 2015, 21 (06) : 1281 - 1288
  • [23] A first-in-human phase I study of the anti-PD-1 antibody PDR001 in patients with advanced solid tumors
    Naing, Aung
    Gelderblom, Hans
    Gainor, Justin F.
    Forde, Patrick M.
    Butler, Marcus
    Lin, Chia-Chi
    Sharma, Sunil
    de Olza, Maria Ochoa
    Schellens, Jan H. M.
    Soria, Jean-Charles
    Taylor, Matthew H.
    Silva, Antonio P.
    Li, Zhonggai
    Bilic, Sanela
    Cameron, Scott
    Infante, Jeffrey R.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [24] Initial findings from a first-in-human, multicenter, open-label study of ATOR-1017, a 4-1BB antibody, in patients with advanced solid malignancies
    Ullenhag, Gustav J.
    Carneiro, Ana
    Smith, Karin Enell
    Schultz, Lena
    Ambarkhane, Sumeet Vijay
    Landstrom, Tova
    Yachnin, Jeffrey
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [25] First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumors
    Elena Elez
    Carlos Gomez-Roca
    Arturo Soto Matos-Pita
    Guillem Argiles
    Thibaud Valentin
    Cinthya Coronado
    Jorge Iglesias
    Teresa Macarulla
    Sarah Betrian
    Salvador Fudio
    Katrin Zaragoza
    Josep Tabernero
    Jean-Pierre Delord
    Investigational New Drugs, 2019, 37 : 674 - 683
  • [26] A Phase I First-in-Human Pharmacokinetic and Pharmacodynamic Study of Serdemetan in Patients with Advanced Solid Tumors
    Tabernero, Josep
    Dirix, Luc
    Schoffski, Patrick
    Cervantes, Andres
    Antonio Lopez-Martin, Jose
    Capdevila, Jaume
    van Beijsterveldt, Ludy
    Platero, Suso
    Hall, Brett
    Yuan, Zhilong
    Knoblauch, Roland
    Zhuang, Sen Hong
    CLINICAL CANCER RESEARCH, 2011, 17 (19) : 6313 - 6321
  • [27] First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumors
    Elez, Elena
    Gomez-Roca, Carlos
    Soto Matos-Pita, Arturo
    Argiles, Guillem
    Valentin, Thibaud
    Coronado, Cinthya
    Iglesias, Jorge
    Macarulla, Teresa
    Betrian, Sarah
    Fudio, Salvador
    Zaragoza, Katrin
    Tabernero, Josep
    Delord, Jean-Pierre
    INVESTIGATIONAL NEW DRUGS, 2019, 37 (04) : 674 - 683
  • [28] Preliminary phase I results from a first-in-human study of EMB-02, a PD-1xLAG-3 bispecific antibody, in patients (pts) with advanced solid tumors
    Day, D.
    Ganju, V.
    Chung, K.
    Si, L.
    Mao, L.
    Aghmesheh, M.
    Hoyer, R.
    Brewin, K.
    Zeng, S.
    Lu, Q.
    Jiang, C.
    Ren, F.
    Wu, X.
    Guo, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S625 - S625
  • [29] MEDI5752, a novel PD-1/CTLA-4 bispecific checkpoint inhibitor for advanced solid tumors: First-in-human study
    Tran, Ben
    Voskoboynik, Mark
    Kim, Sang-We
    Lemech, Charlotte
    Carcereny, Enric
    Rha, Sun Young
    Ahn, Myung-Ju
    Felip, Enriqueta
    Lee, Ki H.
    Alvarez, Eduardo C.
    Yang, James Chih-Hsin
    Ascierto, Paolo A.
    Pulla, Mariano P.
    Freeman, Dan
    Song, Xuyang
    Gainer, Shelby D.
    Mitchell, Patrick
    Achour, Ikbel
    Subramaniam, Deepa S.
    Im, Seock-Ah
    CANCER RESEARCH, 2022, 82 (12)
  • [30] First-in-human phase I dose escalation study of ALG.APV-527, a 5T4 tumor antigen-conditional 4-1BB bispecific antibody, in patients with advanced solid tumors, demonstrates positive safety, signals of biological activity and patients with lasting stable disease
    Marron, T.
    Rosen, S.
    Orr, D.
    Powderly, J., II
    Khaskhely, N.
    Bonham, L.
    Nelson, M.
    Taromino, C.
    Taylor, D.
    Kumer, J.
    Ellmark, P.
    Fritzell, S.
    Ambarkhane, S. V.
    Huebner, D.
    Alahmadi, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S524 - S525
12345